{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T10:04:36Z","timestamp":1790417076000,"version":"4.1.0"},"reference-count":33,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"10","license":[{"start":{"date-parts":[[2018,9,24]],"date-time":"2018-09-24T00:00:00Z","timestamp":1537747200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Hepatology Communications"],"published-print":{"date-parts":[[2018,10,1]]},"abstract":"<jats:p>Dyslipidemia is one of the common risk factors for NAFLD and is associated with cardiovascular (CV) mortality, which is the most common cause of death in NAFLD. Lipid\u2010lowering agents (LLAs) are used to reduce CV events in the general population. Our aim was to assess whether the use of LLAs in patients with NAFLD can reduce the risk of CV mortality. We used the third National Health and Nutrition Examination Survey mortality linked files. Mortality was determined from the National Death Index records through 2011. NAFLD was diagnosed by ultrasound after exclusion of other causes of liver disease. After inclusion and exclusion, the cohort consisted of 2,566 patients with NAFLD (45.8% &lt; 45 years of age, 52.8% male, 75.4% white). Those who were taking LLAs were more likely to be older, non\u2010Hispanic white, and had significantly higher rates of diabetes mellitus (DM), hyperlipidemia, hypertension, metabolic syndrome, and history of CV disease (CVD) (all <jats:italic toggle=\"yes\">P<\/jats:italic>&lt; 0.01). In our multivariate analysis, DM was an independent predictor of overall mortality (adjusted hazard ratio [aHR]: 1.79 [95% confidence interval (CI): 1.40\u20102.30]) and CV mortality (aHR: 1.89 [95% CI: 1.08\u20103.30]). History of CVD was associated with both overall (aHR: 2.03 [95% CI: 1.57\u20102.63]) and CV mortality (aHR: 3.69 [95% CI: 2.23\u20106.08]). In contrast, the use of statins and other LLAs was not associated with reduction in overall (aHR = 0.95 [95% CI: 0.37\u20102.44] and aHR = 1.43 [95% CI: 0.99\u20102.07]) and CV mortality (aHR = 1.20 [95% CI: 0.26\u20105.54] and aHR = 1.63 [95% CI: 0.70\u20103.76]). <jats:italic toggle=\"yes\">Conclusion:<\/jats:italic> The use of statins and other LLAs did not reduce the increased risk of overall or CV mortality in NAFLD.<\/jats:p>","DOI":"10.1002\/hep4.1241","type":"journal-article","created":{"date-parts":[[2018,9,24]],"date-time":"2018-09-24T13:14:57Z","timestamp":1537794897000},"page":"1227-1234","source":"Crossref","is-referenced-by-count":27,"title":["Among Patients With NAFLD, Treatment of Dyslipidemia Does Not Reduce Cardiovascular Mortality"],"prefix":"10.1097","volume":"2","author":[{"given":"Omer","family":"Shahab","sequence":"first","affiliation":[{"name":"Center for Liver Disease, Department of Medicine,Inova Fairfax Medical Campus,Falls Church,VA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rakesh","family":"Biswas","sequence":"additional","affiliation":[{"name":"Center for Liver Disease, Department of Medicine,Inova Fairfax Medical Campus,Falls Church,VA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"Paik","sequence":"additional","affiliation":[{"name":"Betty and Guy Beatty Center for Integrated Research,Inova Health System,Falls Church,VA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haley","family":"Bush","sequence":"additional","affiliation":[{"name":"Betty and Guy Beatty Center for Integrated Research,Inova Health System,Falls Church,VA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9818-0983","authenticated-orcid":false,"given":"Pegah","family":"Golabi","sequence":"additional","affiliation":[{"name":"Betty and Guy Beatty Center for Integrated Research,Inova Health System,Falls Church,VA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9313-577X","authenticated-orcid":false,"given":"Zobair M.","family":"Younossi","sequence":"additional","affiliation":[{"name":"Center for Liver Disease, Department of Medicine,Inova Fairfax Medical Campus,Falls Church,VA"},{"name":"Betty and Guy Beatty Center for Integrated Research,Inova Health System,Falls Church,VA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2018,9,24]]},"reference":[{"key":"hep41241-bib-0001-20240114","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1038\/nrgastro.2017.109","article-title":"Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention","volume":"15","year":"2018","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"hep41241-bib-0002-20240114","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/j.cld.2015.10.001","article-title":"Epidemiology of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis in the United States and the rest of the world","volume":"20","year":"2016","journal-title":"Clin Liver Dis"},{"key":"hep41241-bib-0003-20240114","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1016\/j.metabol.2016.01.012","article-title":"Epidemiology and natural history of non\u2010alcoholic fatty liver disease","volume":"65","year":"2016","journal-title":"Metabolism"},{"key":"hep41241-bib-0004-20240114","doi-asserted-by":"crossref","first-page":"2063","DOI":"10.1056\/NEJMra1503519","article-title":"Cause, pathogenesis, and treatment of nonalcoholic steatohepatitis","volume":"377","year":"2017","journal-title":"N Engl J Med"},{"key":"hep41241-bib-0005-20240114","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1002\/hep.29367","article-title":"The diagnosis and management of nonalcoholic fatty liver disease: practice guidance from the American Association for the Study of Liver Diseases","volume":"67","year":"2018","journal-title":"Hepatology"},{"key":"hep41241-bib-0006-20240114","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.1016\/j.cgh.2014.10.008","article-title":"Severity of nonalcoholic fatty liver disease and progression to cirrhosis are associated with atherogenic lipoprotein profile","volume":"13","year":"2015","journal-title":"Clin Gastroenterol Hepatol"},{"key":"hep41241-bib-0007-20240114","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1016\/j.jhep.2016.04.005","article-title":"Non\u2010alcoholic fatty liver disease and cardiovascular risk: pathophysiological mechanisms and implications","volume":"65","year":"2016","journal-title":"J Hepatol"},{"key":"hep41241-bib-0008-20240114","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1016\/j.cld.2017.06.010","article-title":"Treatment strategies for nonalcoholic fatty liver disease and nonalcoholic steatohepatitis","volume":"21","year":"2017","journal-title":"Clin Liver Dis"},{"key":"hep41241-bib-0009-20240114","doi-asserted-by":"crossref","first-page":"6318","DOI":"10.3748\/wjg.v22.i27.6318","article-title":"Effectiveness of exercise in hepatic fat mobilization in non\u2010alcoholic fatty liver disease: systematic review","volume":"22","year":"2016","journal-title":"World J Gastroenterol"},{"key":"hep41241-bib-0010-20240114","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1002\/hep.29724","article-title":"Current and future therapeutic regimens for non\u2010alcoholic fatty liver disease (NAFLD) and non\u2010alcoholic steatohepatitis (NASH)","volume":"68","year":"2018","journal-title":"Hepatology"},{"key":"hep41241-bib-0011-20240114","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1002\/hep.23719","article-title":"Hepatic lipotoxicity and the pathogenesis of nonalcoholic steatohepatitis: the central role of nontriglyceride fatty acid metabolites","volume":"52","year":"2010","journal-title":"Hepatology"},{"key":"hep41241-bib-0012-20240114","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.tem.2015.11.008","article-title":"The role of cholesterol in the pathogenesis of NASH","volume":"27","year":"2016","journal-title":"Trends Endocrinol Metab"},{"key":"hep41241-bib-0013-20240114","doi-asserted-by":"crossref","first-page":"1765","DOI":"10.1016\/j.bbadis.2015.05.015","article-title":"Recent insights on the role of cholesterol in non\u2010alcoholic fatty liver disease","volume":"1852","year":"2015","journal-title":"Biochim Biophys Acta"},{"key":"hep41241-bib-0014-20240114","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/j.plipres.2012.11.002","article-title":"Cholesterol metabolism and the pathogenesis of non\u2010alcoholic steatohepatitis","volume":"52","year":"2013","journal-title":"Prog Lipid Res"},{"key":"hep41241-bib-0015-20240114","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1055\/s-0032-1306423","article-title":"Dyslipidemia in patients with nonalcoholic fatty liver disease","volume":"32","year":"2012","journal-title":"Semin Liver Dis"},{"key":"hep41241-bib-0016-20240114","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/j.jhep.2015.09.021","article-title":"Statins and non\u2010alcoholic steatohepatitis","volume":"64","year":"2016","journal-title":"J Hepatol"},{"key":"hep41241-bib-0017-20240114","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.dld.2014.07.170","article-title":"The efficacy and safety of statins for the treatment of non\u2010alcoholic fatty liver disease","volume":"47","year":"2015","journal-title":"Dig Liver Dis"},{"key":"hep41241-bib-0018-20240114","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.numecd.2016.09.011","article-title":"Under\u2010prescription of statins in patients with non\u2010alcoholic fatty liver disease","volume":"27","year":"2017","journal-title":"Nutr Metab Cardiovasc Dis"},{"key":"hep41241-bib-0019-20240114","doi-asserted-by":"crossref","first-page":"2950","DOI":"10.1210\/jc.2017-00867","article-title":"Liver safety of statins in prediabetes or T2DM and nonalcoholic steatohepatitis: post hoc analysis of a randomized trial","volume":"102","year":"2017","journal-title":"J Clin Endocrinol Metab"},{"key":"hep41241-bib-0020-20240114","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1097\/MAJ.0b013e3181e15da8","article-title":"Hepatotoxicity fears contribute to underutilization of statin medications by primary care physicians","volume":"340","year":"2010","journal-title":"Am J Med Sci"},{"key":"hep41241-bib-0021-20240114","first-page":"47","article-title":"The National Lipid Association's Statin Safety Task Force. An assessment by the Statin Liver Safety Task Force: 2014 update","volume":"8","year":"2014","journal-title":"J Clin Lipidol"},{"key":"hep41241-bib-0022-20240114","first-page":"84","article-title":"Statin use is not associated with liver related mortality","volume":"13","year":"2013","journal-title":"Ann Hepatol"},{"key":"hep41241-bib-0023-20240114","first-page":"S1","article-title":"2013 ACC\/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology\/American Heart Association Task Force on Practice Guidelines","volume":"129","year":"2014","journal-title":"Circulation"},{"key":"hep41241-bib-0024-20240114","first-page":"928","article-title":"Intensity of statin treatment and mortality\u2010reply","volume":"2","year":"2017","journal-title":"JAMA Cardiol"},{"key":"hep41241-bib-0025-20240114","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1016\/j.cgh.2011.12.039","article-title":"Independent association between nonalcoholic fatty liver disease and cardiovascular disease in the US population","volume":"10","year":"2012","journal-title":"Clin Gastroenterol Hepatol"},{"key":"hep41241-bib-0028-20240114","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1056\/NEJMoa1114248","article-title":"Estimating glomerular filtration rate from serum creatinine and cystatin C","volume":"367","year":"2012","journal-title":"N Engl J Med"},{"key":"hep41241-bib-0030-20240114","first-page":"319","article-title":"Nonalcoholic fatty liver disease in lean individuals in the United States","volume":"9","year":"2012","journal-title":"Medicine"},{"key":"hep41241-bib-0034-20240114","first-page":"796","article-title":"Safety and impact on cardiovascular events of long\u2010term multifactorial treatment in patients with metabolic syndrome and abnormal liver function tests: a post hoc analysis of the randomised ATTEMPT study","volume":"7","year":"2011","journal-title":"Arch Med Sci"},{"key":"hep41241-bib-0035-20240114","doi-asserted-by":"crossref","first-page":"3846","DOI":"10.1016\/j.ijcard.2013.06.024","article-title":"Effect of intensive lipid lowering with atorvastatin on cardiovascular outcomes in coronary heart disease patients with mild\u2010to\u2010moderate baseline elevations in alanine aminotransferase levels","volume":"168","year":"2013","journal-title":"Int J Cardiol"},{"key":"hep41241-bib-0036-20240114","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1002\/phar.1190","article-title":"Pharmacologic therapy for nonalcoholic fatty liver disease in adults","volume":"33","year":"2013","journal-title":"Pharmacotherapy"},{"key":"hep41241-bib-0037-20240114","first-page":"1792","article-title":"Statin use and reduced cancer\u2010related mortality","volume":"367","year":"2013","journal-title":"N Engl J Med"},{"key":"hep41241-bib-0038-20240114","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1002\/cld.671","article-title":"The gut microbiome and nonalcoholic fatty liver disease: gut microbiome and NAFLD","volume":"10","year":"2017","journal-title":"Clin Liver Dis"},{"key":"hep41241-bib-0039-20240114","doi-asserted-by":"crossref","first-page":"e295","DOI":"10.1016\/S1470-2045(18)30095-0","article-title":"Gut dysbiosis: a potential link between increased cancer risk in ageing and inflammaging","volume":"19","year":"2018","journal-title":"Lancet Oncol"}],"container-title":["Hepatology Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fhep4.1241","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/hep4.1241","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/hep4.1241","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.lww.com\/02009842-201810010-00010","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,1,14]],"date-time":"2024-01-14T16:06:56Z","timestamp":1705248416000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/02009842-201810010-00010"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,9,24]]},"references-count":33,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2018]]}},"URL":"https:\/\/doi.org\/10.1002\/hep4.1241","relation":{},"ISSN":["2471-254X","2471-254X"],"issn-type":[{"value":"2471-254X","type":"print"},{"value":"2471-254X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,9,24]]}}}